FYI: The GLP-1 off-ramp just got real. A new procedure might solve weight regain.

This one's gonna move fast.

Yesterday, researchers quietly dropped the first real answer to the biggest unsolved problem in GLP-1 medicine, what to do when you stop the drug, and the mainstream coverage hasn't caught up yet.

If you read Issue #7 yesterday, the last reader question (the nurse whose mom keeps sending her TikToks) and Q4 (what happens when you stop) both circle the same anxiety: GLP-1s work, but the day you stop, the weight comes back. Usually within 18 months. Usually fast.

Today's issue is the first credible evidence that might not be true forever.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: The GLP-1 off-ramp just got real. A one-time procedure might solve weight regain.

A company called Fractyl Health (NASDAQ: GUTS) released data yesterday ahead of a Digestive Disease Week 2026 presentation scheduled for May 4 in Chicago. The procedure is called duodenal mucosal resurfacing (DMR), trade name Revita. It's a 30 to 45 minute outpatient endoscopy that uses controlled heat to ablate and regenerate the lining of the duodenum, the first section of the small intestine just below the stomach.

The theory: chronic high-fat, high-sugar diets damage the duodenum in ways that mess up how your body senses and responds to food. Revita resurfaces the damaged lining and triggers regrowth of healthier tissue, "resetting" metabolism at a lower body weight after you've lost the weight on a GLP-1.

The theory has been around for a decade. The randomized, blinded, sham-controlled evidence showing it actually works just arrived.

Here's what happened in the trial.

Researchers at Dartmouth Health led by Dr. Shelby Sullivan took 45 adults with obesity who had no prior GLP-1 use and no diabetes. All participants started tirzepatide (the active ingredient in Mounjaro and Zepbound) and stayed on it until they had lost at least 15% of their body weight. Then they stopped the drug. At least one week after stopping, patients were randomized 2:1 to either the actual Revita procedure (29 patients) or a sham endoscopic procedure (16 patients). Both groups received structured lifestyle counseling. Neither the patients nor the observers knew who got which.

At 3 months, the results were dramatic.

The Revita group didn't just maintain their tirzepatide weight loss. They lost another 2.5% of body weight after stopping the drug. The sham group regained 10% of body weight in 3 months, which matches what the Oxford meta-analysis in the British Medical Journal found: after stopping a GLP-1, people regain at about 0.4 kg per month, roughly 4x faster than weight regain after stopping diet-and-exercise programs.

At 6-month follow-up, Revita patients maintained more than 80% of their total weight loss. Sham patients regained roughly twice as much as the Revita group. No serious adverse events related to the procedure were reported.

For the first time, there is randomized, blinded evidence that a one-time outpatient procedure may lock in GLP-1 weight loss without indefinite injections.

Approximately 70% of GLP-1 users stop taking the drug at some point. Cost, side effects, insurance changes, not wanting to be on a drug forever. An Oxford meta-analysis of 37 studies and 9,300 patients found that people who stop typically return to their pre-treatment weight in about 1.7 years. The health benefits (blood pressure, cholesterol, blood sugar control) reverse within 1 to 1.4 years.

Until now, the only answer was "don't stop." Or "taper slowly." Or "hope you can hold it with diet and exercise" (most people can't).

Revita is the first actual intervention backed by randomized data.

Fractyl got FDA Breakthrough Device designation specifically for "weight maintenance in people with obesity who discontinue GLP-1 drugs." That's a regulatory category that didn't exist two years ago. Every other obesity treatment (drugs, bariatric surgery, programs) targets weight LOSS. Revita targets post-loss MAINTENANCE.

If the pivotal trial hits its endpoints, "post-GLP-1 weight maintenance" becomes a real market that every obesity-adjacent company (Novo, Lilly, bariatric surgery centers, wellness platforms) will have to reckon with.

Gastric bypass has always worked better for metabolic disease than gastric banding. Researchers figured out decades ago that it was partly because bypass reroutes food away from the duodenum. DMR achieves something similar (duodenal mucosal reset) without permanent anatomical changes, without incisions, without general anesthesia. Thirty to 45 minutes, outpatient, go home same day.

Translation: if you're planning to stop your GLP-1 in the next 12 months, Revita is not an option for you. If you're thinking about 2 to 3 years out, it might be.

The REMAIN-1 Midpoint Cohort excluded both diabetics and anyone who had used a GLP-1 before. That's a narrow population of relatively healthy adults who specifically lost weight on tirzepatide. Most real-world people wanting a GLP-1 off-ramp are diabetic, older, on multiple medications, or have been on the drug for years. Generalizability to the broader GLP-1 population is an open question.

The procedure also has to be done correctly. Fractyl's pivotal trial required ablation lengths of at least 14 cm (mean was over 16 cm). Shorter ablations don't produce the same results. That means commercial rollout depends on physician training and credentialing, which will slow deployment even after approval.

Three things to take into your next doctor conversation.

45-patient trials become 315-patient trials become approvals, or they don't. Nine of every ten pivotal obesity trials miss expectations at scale. The Q4 2026 pivotal readout is where this either becomes a real category or falls apart. Track it. Don't bet on it.

Based on the REMAIN-1 design, the target patient is someone who has lost 15%+ body weight on a GLP-1, doesn't have diabetes, has a BMI in the 30 to 45 range, and wants to stop the drug. If that's you eventually, this is your procedure to watch. If you're diabetic or on a GLP-1 for reasons beyond pure weight loss, expect separate future trials.

Revita prevents fat regain. It does not rebuild muscle lost during weight loss. If you took our Issue #7 muscle-loss answer seriously, that plan (0.8 to 1.2g protein per pound of lean body mass, resistance training 2-3x per week) is still your responsibility. Revita solves one problem. Body composition is still on you.

Text your doctor this: "I've been following the REMAIN-1 trial results for duodenal mucosal resurfacing and the Revita procedure. It's not approved yet, but the data looks promising for preventing weight regain after stopping a GLP-1. Can we talk about what my off-ramp plan would look like if this becomes available, and what clinical trial enrollment options might exist before then?"

Copy, paste, send.

The "Ozempic is forever" narrative is starting to crack. For two years, the universal framing has been "you have to take this the rest of your life or you'll regain everything." Revita is the first clinical evidence that might not be true. Culturally, this reframes the entire decision to start a GLP-1 in the first place.

Digestive Disease Week 2026 is going to be a moment. May 2-5 in Chicago. Dr. Sullivan presents on Monday May 4 at 8:30 AM CDT, abstract 642. Expect a second wave of media coverage during the conference week. Off Label is about 10 days ahead of the mainstream wave.

DDW moderator Dr. Loren Laine at Yale publicly commented on the findings. Quote from his Medscape interview: "In general, people aren't good at taking medications, and frankly if a certain number of people stop them, the quality of life worsens and the costs increase as weight is regained, so I think it's important." (Not a financial conflict of interest, not affiliated with Fractyl, and he chairs the conference. When the guy running the meeting publicly validates your data, that matters.)

The bariatric surgery industry is paying attention. If DMR works at scale, the calculus around bariatric surgery shifts. Why commit to permanent anatomical changes when a 45-minute endoscopy might deliver similar metabolic benefits? Bariatric surgeons will argue the lifetime durability question, which is fair. That debate is just getting started.

"Post-GLP-1 weight maintenance" is going to be a category you hear about constantly for the next 18 months. Remember the phrase.

Watch this: Fractyl Health (NASDAQ: GUTS). Small-cap medical device company. Stock has been trading between $0.58 and $2.20 in recent sessions, with a 52-week range of $0.38 to $3.03. The entire thesis hinges on the REMAIN-1 Pivotal Cohort 6-month readout expected early Q4 2026. Analyst consensus is "Strong Buy" across 4-5 firms, with 12-month price targets ranging from $3.60 on the low end to $10 on the high end, averaging around $5.40 to $7.40. Binary outcome stock. If pivotal data hits, the upside case is 5x to 15x. If it misses, the drop will be sharp. Off Label is not a financial advice publication. We're saying: watch the Q4 readout because it will determine whether this whole story is real.

Tomorrow: the practical playbook. If you're on a GLP-1 right now and wondering how to taper, stop, or transition, we're going through the evidence-based approach your doctor may not have walked you through.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions. Mentions of publicly traded companies (including NASDAQ: GUTS) are for informational and tracking purposes only and do not constitute financial advice or investment recommendations.